NCT02054351 - Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 6, 2014

Primary Completion Date

October 28, 2015

Study Completion Date

October 28, 2015

Conditions

Ovarian Cancer

Interventions

DRUG

IMAB027

Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2

Trial Locations (9)

1090

UZ Brussels, Brussels

1307

Gemeinschaftspraxis Hämatologie-Onkologie, Dresden

3000

UZ Leuven, Leuven

13353

Charité - Universitätsmedizin Berlin, Berlin

24105

UKSH Kiel, Kiel

55131

Universitätsmedizin Mainz, Mainz

69120

Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Universitätsklinikum Heidelberg, Heidelberg

72076

Universitäts-Frauenklinik (UFK) Tübingen, Tübingen

89075

Universitätsklinikum Ulm, Frauenklinik, Ulm